196 related articles for article (PubMed ID: 22738271)
1. 7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists.
Baraldi PG; Saponaro G; Moorman AR; Romagnoli R; Preti D; Baraldi S; Ruggiero E; Varani K; Targa M; Vincenzi F; Borea PA; Aghazadeh Tabrizi M
J Med Chem; 2012 Jul; 55(14):6608-23. PubMed ID: 22738271
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of quinolinyl and isoquinolinyl phenyl ketones as novel agonists for the cannabinoid CB2 receptor.
Reux B; Nevalainen T; Raitio KH; Koskinen AM
Bioorg Med Chem; 2009 Jul; 17(13):4441-7. PubMed ID: 19477133
[TBL] [Abstract][Full Text] [Related]
3. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
Stern E; Muccioli GG; Bosier B; Hamtiaux L; Millet R; Poupaert JH; Hénichart JP; Depreux P; Goossens JF; Lambert DM
J Med Chem; 2007 Nov; 50(22):5471-84. PubMed ID: 17915849
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
[TBL] [Abstract][Full Text] [Related]
5. Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
Pasquini S; De Rosa M; Ligresti A; Mugnaini C; Brizzi A; Caradonna NP; Cascio MG; Bolognini D; Pertwee RG; Di Marzo V; Corelli F
Eur J Med Chem; 2012 Dec; 58():30-43. PubMed ID: 23085772
[TBL] [Abstract][Full Text] [Related]
6. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
Stern E; Muccioli GG; Millet R; Goossens JF; Farce A; Chavatte P; Poupaert JH; Lambert DM; Depreux P; Hénichart JP
J Med Chem; 2006 Jan; 49(1):70-9. PubMed ID: 16392793
[TBL] [Abstract][Full Text] [Related]
7. 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands.
Piscitelli F; Ligresti A; La Regina G; Gatti V; Brizzi A; Pasquini S; Allarà M; Carai MA; Novellino E; Colombo G; Di Marzo V; Corelli F; Silvestri R
Eur J Med Chem; 2011 Nov; 46(11):5641-53. PubMed ID: 21996466
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists.
Aghazadeh Tabrizi M; Baraldi PG; Saponaro G; Moorman AR; Romagnoli R; Preti D; Baraldi S; Ruggiero E; Tintori C; Tuccinardi T; Vincenzi F; Borea PA; Varani K
J Med Chem; 2013 Jun; 56(11):4482-96. PubMed ID: 23697626
[TBL] [Abstract][Full Text] [Related]
9. New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.
Manera C; Cascio MG; Benetti V; Allarà M; Tuccinardi T; Martinelli A; Saccomanni G; Vivoli E; Ghelardini C; Di Marzo V; Ferrarini PL
Bioorg Med Chem Lett; 2007 Dec; 17(23):6505-10. PubMed ID: 17942307
[TBL] [Abstract][Full Text] [Related]
10. Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.
Worm K; Weaver DG; Green RC; Saeui CT; Dulay DM; Barker WM; Cassel JA; Stabley GJ; DeHaven RN; LaBuda CJ; Koblish M; Brogdon BL; Smith SA; Dolle RE
Bioorg Med Chem Lett; 2009 Sep; 19(17):5004-8. PubMed ID: 19646869
[TBL] [Abstract][Full Text] [Related]
11. 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.
El Bakali J; Muccioli GG; Renault N; Pradal D; Body-Malapel M; Djouina M; Hamtiaux L; Andrzejak V; Desreumaux P; Chavatte P; Lambert DM; Millet R
J Med Chem; 2010 Nov; 53(22):7918-31. PubMed ID: 20979417
[TBL] [Abstract][Full Text] [Related]
12. Microwave-assisted synthesis of quinoline, isoquinoline, quinoxaline and quinazoline derivatives as CB2 receptor agonists.
Saari R; Törmä JC; Nevalainen T
Bioorg Med Chem; 2011 Jan; 19(2):939-50. PubMed ID: 21215643
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel class of selective human CB1 inverse agonists.
Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM
Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.
Lange JH; van der Neut MA; Wals HC; Kuil GD; Borst AJ; Mulder A; den Hartog AP; Zilaout H; Goutier W; van Stuivenberg HH; van Vliet BJ
Bioorg Med Chem Lett; 2010 Feb; 20(3):1084-9. PubMed ID: 20031412
[TBL] [Abstract][Full Text] [Related]
15. 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
Rempel V; Volz N; Hinz S; Karcz T; Meliciani I; Nieger M; Wenzel W; Bräse S; Müller CE
J Med Chem; 2012 Sep; 55(18):7967-77. PubMed ID: 22916707
[TBL] [Abstract][Full Text] [Related]
16. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo.
Lunn CA; Fine JS; Rojas-Triana A; Jackson JV; Fan X; Kung TT; Gonsiorek W; Schwarz MA; Lavey B; Kozlowski JA; Narula SK; Lundell DJ; Hipkin RW; Bober LA
J Pharmacol Exp Ther; 2006 Feb; 316(2):780-8. PubMed ID: 16258021
[TBL] [Abstract][Full Text] [Related]
17. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
Chu GH; Saeui CT; Worm K; Weaver DG; Goodman AJ; Broadrup RL; Cassel JA; DeHaven RN; LaBuda CJ; Koblish M; Brogdon B; Smith S; Le Bourdonnec B; Dolle RE
Bioorg Med Chem Lett; 2009 Oct; 19(20):5931-5. PubMed ID: 19736007
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
Muccioli GG; Wouters J; Charlier C; Scriba GK; Pizza T; Di Pace P; De Martino P; Poppitz W; Poupaert JH; Lambert DM
J Med Chem; 2006 Feb; 49(3):872-82. PubMed ID: 16451053
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
Manera C; Benetti V; Castelli MP; Cavallini T; Lazzarotti S; Pibiri F; Saccomanni G; Tuccinardi T; Vannacci A; Martinelli A; Ferrarini PL
J Med Chem; 2006 Oct; 49(20):5947-57. PubMed ID: 17004710
[TBL] [Abstract][Full Text] [Related]
20. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
